课题基金 / 基金详情

Peroxynitrate neutralizing agents for stroke therapy

Peroxynitrate neutralizing agents for stroke therapy
用于中风治疗的过氧硝酸盐中和剂
批准号:
6482163
负责人:
CSABA SZABO
金额:
$72.88万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-06 至 2004-08-31

项目摘要

项目成果

CSABA SZABO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):Nitric oxide (NO) and peroxynitrite are reactive, short-lived species that are important mediators of cellular injury in reperfusion injury associated with ischemic stroke. The applicants are developing novel classes of peroxynitrite neutrahzer compounds with protective effects in stroke. In this proposal, we present evidence that such agents are (1) inhibitors of cell injury triggered by various oxidants and free radicals (2) exert protective effects in a rat model of stroke . The specific aims of the present proposal are the following: (1) to synthesize large quantities of SEGED as well as FP15 and FP16, members of the applicants' second generation peroxynitrite decomposition catalyst compounds, and perform extensive and definitive stroke studies with a wide range of dosing regimen and delayed administration. Additional aims of the current submission are (2) to perform in-house toxicity testing, to determine the therapeutic ratio of each of the compounds. Based on the outcome of (1) and (2), we will select a lead drug candidate for further, formal preclinical toxicity studies. The final aim of the current studies (3) is to perform pre-clinical pharmaceutical testing (advanced toxicity determinations, pathology, stability, pharmacokinetics, in vivo efficacy), in order to reach the stage of investigational drug application to the FDA and Phase 1 clinical trial with the lead peroxynitrite decompositton catalyst for the treatment of isehem c stroke.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
  • 批准号:
    9251701
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2017
  • 负责人:
    CSABA SZABO
  • 依托单位:
Inhibition of Bacterial and Host-Derived H2S Production for the Therapeutic Enhancement of Anti-Bacterial Host Defense
Regulation of cellular bioenergetics by hydrogen sulfide
Poly(ADP-ribose) synthetase inhibition and diabetes
海外基金